DexCom (NASDAQ:DXCM) had its price target boosted by analysts at Piper Jaffray Companies from $182.00 to $200.00 in a note issued to investors on Thursday, Stock Target Advisor reports. The firm currently has an “overweight” rating on the medical device company’s stock. Piper Jaffray Companies’ price target would suggest a potential upside of 1.74% from the company’s previous close. Piper Jaffray Companies also issued estimates for DexCom’s Q4 2019 earnings at $0.55 EPS, Q1 2020 earnings at $0.11 EPS, Q4 2020 earnings at $0.71 EPS, Q1 2021 earnings at $0.23 EPS and Q2 2021 earnings at $0.40 EPS.
DXCM has been the topic of several other reports. UBS Group lifted their target price on DexCom from $160.00 to $185.00 and gave the stock a “neutral” rating in a report on Thursday. Stifel Nicolaus lifted their target price on DexCom from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday. BidaskClub upgraded DexCom from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Jefferies Financial Group lifted their target price on DexCom from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Morgan Stanley lifted their target price on DexCom from $175.00 to $202.00 and gave the stock an “equal weight” rating in a report on Thursday. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and an average target price of $190.67.
DXCM stock traded up $1.88 during midday trading on Thursday, hitting $196.58. 77,631 shares of the company’s stock were exchanged, compared to its average volume of 651,959. The stock’s fifty day moving average price is $154.75 and its 200-day moving average price is $145.88. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05. The company has a market cap of $14.00 billion, a PE ratio of 656.87 and a beta of 0.64. DexCom has a one year low of $105.05 and a one year high of $200.80.
DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.45. The firm had revenue of $396.30 million for the quarter, compared to analyst estimates of $348.99 million. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The company’s revenue for the quarter was up 48.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.17 earnings per share. On average, analysts expect that DexCom will post 0.94 EPS for the current year.
In other news, insider Andrew K. Balo sold 9,107 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $151.56, for a total value of $1,380,256.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 10,000 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $157.50, for a total value of $1,575,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 104,014 shares of company stock worth $16,183,576. Corporate insiders own 1.80% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Jennison Associates increased its position in DexCom by 182.7% during the third quarter. Jennison Associates now owns 964,112 shares of the medical device company’s stock worth $82,779,000 after buying an additional 623,059 shares during the last quarter. Gerstein Fisher acquired a new position in DexCom during the third quarter worth approximately $314,000. Janus Capital Management acquired a new position in DexCom during the third quarter worth approximately $8,500,000. Assetmark acquired a new position in DexCom during the third quarter worth approximately $0. Finally, Beacon Capital Management acquired a new position in DexCom during the fourth quarter worth approximately $0. Institutional investors own 96.19% of the company’s stock.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Buy Rating
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.